257 related articles for article (PubMed ID: 31606419)
1. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
[TBL] [Abstract][Full Text] [Related]
2. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Laetsch TW; Maude SL; Rives S; Hiramatsu H; Bittencourt H; Bader P; Baruchel A; Boyer M; De Moerloose B; Qayed M; Buechner J; Pulsipher MA; Myers GD; Stefanski HE; Martin PL; Nemecek E; Peters C; Yanik G; Khaw SL; Davis KL; Krueger J; Balduzzi A; Boissel N; Tiwari R; O'Donovan D; Grupp SA
J Clin Oncol; 2023 Mar; 41(9):1664-1669. PubMed ID: 36399695
[No Abstract] [Full Text] [Related]
3. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
Levine JE; Grupp SA; Pulsipher MA; Dietz AC; Rives S; Myers GD; August KJ; Verneris MR; Buechner J; Laetsch TW; Bittencourt H; Baruchel A; Boyer MW; De Moerloose B; Qayed M; Davies SM; Phillips CL; Driscoll TA; Bader P; Schlis K; Wood PA; Mody R; Yi L; Leung M; Eldjerou LK; June CH; Maude SL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34353848
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
[TBL] [Abstract][Full Text] [Related]
5. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á; Alonso-Saladrigues A; Herrero B; Caballero-Velázquez T; Galán-Gómez V; Panesso M; Torrebadell M; Delgado-Serrano J; Pérez de Soto C; Faura A; González-Martínez B; Castillo-Robleda A; Diaz-de-Heredia C; Pérez-Martínez A; Pérez-Hurtado JM; Rives S; Pérez-Simón JA
Front Immunol; 2023; 14():1280580. PubMed ID: 38292483
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
[TBL] [Abstract][Full Text] [Related]
8. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
V Stackelberg A; Jäschke K; Jousseaume E; Templin C; Jeratsch U; Kosmides D; Steffen I; Gökbuget N; Peters C
Leukemia; 2023 Dec; 37(12):2346-2355. PubMed ID: 37880478
[TBL] [Abstract][Full Text] [Related]
9. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Dreyling M; Fowler NH; Dickinson M; Martinez-Lopez J; Kolstad A; Butler J; Ghosh M; Popplewell L; Chavez JC; Bachy E; Kato K; Harigae H; Kersten MJ; Andreadis C; Riedell PA; Ho PJ; Pérez-Simón JA; Chen AI; Nastoupil LJ; von Tresckow B; María Ferreri AJ; Teshima T; Patten PEM; McGuirk JP; Petzer AL; Offner F; Viardot A; Zinzani PL; Malladi R; Paule I; Zia A; Awasthi R; Han X; Germano D; O'Donovan D; Ramos R; Maier HJ; Masood A; Thieblemont C; Schuster SJ
Blood; 2024 Apr; 143(17):1713-1725. PubMed ID: 38194692
[TBL] [Abstract][Full Text] [Related]
10. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH; Dickinson M; Dreyling M; Martinez-Lopez J; Kolstad A; Butler J; Ghosh M; Popplewell L; Chavez JC; Bachy E; Kato K; Harigae H; Kersten MJ; Andreadis C; Riedell PA; Ho PJ; Pérez-Simón JA; Chen AI; Nastoupil LJ; von Tresckow B; Ferreri AJM; Teshima T; Patten PEM; McGuirk JP; Petzer AL; Offner F; Viardot A; Zinzani PL; Malladi R; Zia A; Awasthi R; Masood A; Anak O; Schuster SJ; Thieblemont C
Nat Med; 2022 Feb; 28(2):325-332. PubMed ID: 34921238
[TBL] [Abstract][Full Text] [Related]
11. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study.
Laetsch T; Zhang J; Yang H; Xie Y; Zhang D; Garrison L
Appl Health Econ Health Policy; 2024 Apr; ():. PubMed ID: 38683438
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á; Alonso-Saladrigues A; Herrero B; Caballero-Velázquez T; Galán-Gómez V; Panesso M; Torrebadell M; Delgado-Serrano J; Pérez de Soto C; Faura A; González-Martínez B; Castillo-Robleda A; Diaz-de-Heredia C; Pérez-Martínez A; Pérez-Hurtado JM; Rives S; Pérez-Simón JA
Front Immunol; 2024; 15():1373852. PubMed ID: 38384474
[TBL] [Abstract][Full Text] [Related]
13. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Martin TG; Moreau P; Usmani SZ; Garfall A; Mateos MV; San-Miguel JF; Oriol A; Nooka AK; Rosinol L; Chari A; Karlin L; Krishnan A; Bahlis N; Popat R; Besemer B; Martínez-López J; Delforge M; Trancucci D; Pei L; Kobos R; Fastenau J; Gries KS; van de Donk NWCJ
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):194-202. PubMed ID: 38052709
[TBL] [Abstract][Full Text] [Related]
14. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy.
Gye A; Lourenco RA; Goodall S
Value Health; 2024 Apr; 27(4):415-424. PubMed ID: 38301961
[TBL] [Abstract][Full Text] [Related]
15. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.
Forsberg MH; Das A; Saha K; Capitini CM
Ther Clin Risk Manag; 2018; 14():1573-1584. PubMed ID: 30233192
[TBL] [Abstract][Full Text] [Related]
16. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.
Phillips T; Lugtenburg P; Kalsekar A; Mutebi A; Wang A; Blaedel J; Kosa K; Martin S; Sacchi M; Kilavuz N; Thieblemont C
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e78-e87.e2. PubMed ID: 38151388
[TBL] [Abstract][Full Text] [Related]
17. New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.
Jordaens S; Cooksey L; Freire Boullosa L; Van Tendeloo V; Smits E; Mills KI; Orchard KH; Guinn BA
Cancer Immunol Immunother; 2020 May; 69(5):867-877. PubMed ID: 31970440
[TBL] [Abstract][Full Text] [Related]
18. Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians.
Saltman D; Barlev A; Seshagiri D; Katsoulis I; Lin V; Barber B
BMC Cancer; 2015 Oct; 15():771. PubMed ID: 26498125
[TBL] [Abstract][Full Text] [Related]
19. InsT-ALLing CD7 chimeric antigen receptors before transplantation.
Delgado J
Br J Haematol; 2024 Apr; ():. PubMed ID: 38676290
[TBL] [Abstract][Full Text] [Related]
20. Three-year update outcomes of the first chimeric antigen receptor-T therapy for children and young adults with relapsed/refractory acute lymphoblastic leukemia.
Nakayama H
Transl Pediatr; 2024 Apr; 13(4):535-536. PubMed ID: 38715679
[No Abstract] [Full Text] [Related]
[Next] [New Search]
